Article Information
vol. 7 no. 310 ra11
PubMed:
Published By:
Print ISSN:
Online ISSN:
History:
- Received July 8, 2013
- Accepted December 29, 2013
- .
Copyright & Usage:
Copyright © 2014, American Association for the Advancement of Science
Research ArticleCancer
STAT3 Induction of miR-146b Forms a Feedback Loop to Inhibit the NF-κB to IL-6 Signaling Axis and STAT3-Driven Cancer Phenotypes
- Michael Xiang1,
- Nicolai J. Birkbak2,*,
- Vida Vafaizadeh3,
- Sarah R. Walker1,4,
- Jennifer E. Yeh1,
- Suhu Liu1,
- Yasmin Kroll1,
- Mark Boldin5,†,
- Konstantin Taganov5,‡,
- Bernd Groner3,
- Andrea L. Richardson2, and
- David A. Frank1,4,§
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- 2Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02215, USA.
- 3Georg-Speyer-Haus, Institute for Biomedical Research, D-60956 Frankfurt, Germany.
- 4Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02215, USA.
- 5Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.
- ↵§Corresponding author. E-mail: david_frank{at}dfci.harvard.edu
-
↵* Present address: Department of Systems Biology, Technical University of Denmark, 2800 Lyngby, Denmark.
-
↵† Present address: Department of Molecular and Cellular Biology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
-
↵‡ Present address: EMD Millipore, 28820 Single Oak Drive, Temecula, CA 92590, USA.
See allHide authors and affiliations
Science Signaling 28 Jan 2014:
Vol. 7, Issue 310, pp. ra11
DOI: 10.1126/scisignal.2004497
Vol. 7, Issue 310, pp. ra11
DOI: 10.1126/scisignal.2004497
Michael Xiang
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Nicolai J. Birkbak
2Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02215, USA.
Vida Vafaizadeh
3Georg-Speyer-Haus, Institute for Biomedical Research, D-60956 Frankfurt, Germany.
Sarah R. Walker
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
4Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02215, USA.
Jennifer E. Yeh
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Suhu Liu
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Yasmin Kroll
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Mark Boldin
5Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.
Konstantin Taganov
5Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.
Bernd Groner
3Georg-Speyer-Haus, Institute for Biomedical Research, D-60956 Frankfurt, Germany.
Andrea L. Richardson
2Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02215, USA.
David A. Frank
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
4Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02215, USA.
